If your sample fails you have plenty time for redraw. Early detection of either chromosomal or structural anomalies allows more time in terms of pregnancy management for those conditions. We recommend to take the NIPT along with our comprehensive early anomaly scan (10 Weeks Scan) as soon as possible – 10 weeks. Any invasive testing carries a small risk of miscarriage. If the results are positive (high chance) follow-up invasive testing is needed to get a definite diagnosis. NIPT is a screening test, meaning that NIPT cannot give a definitive answer about whether a baby has Down’s syndrome or other tested chromosomal conditions. However, NIPT can detect a relatively small proportion (about 15%) of all fetal anomalies, because the vast majority of fetal anomalies are physical (structural) and not chromosomal. The limitation of Panorama NIPT is its long results reporting time (up to 10 working days) which is a result of sample shipping to US based Lab.Īlthough cfDNA is a relatively new genetic test, it has been proven to be superior to any other screening tests for Down’s Syndrome, including the Combined Screening Test (CST) used by the NHS. Panorama AI NIPT (non invasive prenatal screening) is an advanced NIPT, based on state-of-the-art algorithms, it has lower sample failure rate comparing with Harmony Test and its price is more affordable for the future parents. After careful consideration we have chosen our second NIPT provider which is Panorama AI. Currently there are many other brands of NIPT, which provide similar or better performance. We have experience of using Harmony for many years.

Harmony Prenatal Test is a trade name of the cfDNA test. Harmony Test is a well known NIPT brand by Ariosa/Roche. Placental cfDNA is usually identical to the DNA of the baby and testing it provides an opportunity for early detection of particular chromosomal anomalies without harming the baby.

NIPT is based on the assessment of small DNA fragments from a baby’s placenta (named ‘cell-free DNA’ or ‘cfDNA’) that are disseminated in the blood of every pregnant mother. Non-Invasive Prenatal Testing (NIPT) or alternatively Non-Invasive Prenatal Screening (NIPS) is a screening method for determining the chance that a baby will be born with Down’s syndrome or other chromosomal anomalies. *** Panorama Al with Microdeletion Panel and Vistara NIPT for single-gene mutations across 30 genes add-on options. The positive or inconclusive results of the tests may be NOT covered by NHS and you may require private genetic counselling and possible private invasive test (CVS or amniocentesis) for your own expense. It can have higher false positive rate and also inconclusive results. ** Triploidy, Turner Syndrome (45X) and sex chromosome aneuploidy NIPT screening has limited clinical validation data. The data from this study showed 83-99.9% sensitivity, 53% positive predictive value (PPV) and just 0.05% false positive rate. * Panorama AI for Di George Syndrome was validated in SMART, the largest prospective NIPT study (2022), combining artificial intelligence (AI) with Natera’s proprietary SNP-based methodology to improve both accuracy and the positive predictive value (PPV) for 22q deletions. The data taken from the clinical data published by Roche and Natera.

Harmony test